A single measurement of BCR-ABL1 transcripts 3 months after imatinib treatment is the best way to identify the patients who will not respond well, according to a study of 282 patients with chronic-phase chronic myeloid leukemia. Patients with elevated transcript levels at 3 months had a reduced overall survival; thus, measuring BCR-ABL1 levels at this time point might allow earlier clinical intervention.
ORIGINAL RESEARCH PAPER
Marin, D. et al. Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. J. Clin. Oncol. doi:10.1200/JCO.2011.38.6565
Rights and permissions
About this article
Cite this article
BCR-ABL1 level at 3 months predicts outcome. Nat Rev Clin Oncol 9, 4 (2012). https://doi.org/10.1038/nrclinonc.2011.194
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2011.194
